Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease - Wikidata - wikimedia - TriplyDB

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q27012625

about

Combined aclidinium bromide and long-acting beta 2 -agonist for COPD Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis Positioning new pharmacotherapies for COPD Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD A review of nebulized drug delivery in COPD Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.β2 adrenergic agonist suppresses eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.Advances in device and formulation technologies for pulmonary drug delivery.Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation.The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL Study KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and β2 agonists in combination or combined into a single molecule.Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.Recent advances in COPD disease management with fixed-dose long-acting combination therapies.Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date

P2860

Q24187613-D5C4F8FE-B780-41FD-B9F9-A84B164A86BD Q26776095-800D68AF-3BFE-4ABF-BF78-DBC3B0A2E5EF Q26777927-BFF7C290-E016-4660-9263-0CBBB47067ED Q26782484-E775115C-B6F0-4EB4-B5D4-A7696DFD4BC1 Q26798659-B4F7C977-A1D9-4D67-AC2D-ADAD526A75F7 Q26801134-9220866B-816D-4A80-8378-FC33C0E1A2D1 Q26825822-7ADC263E-B728-47D2-9A85-8B96B1DF827A Q28075295-0FB81729-6524-4507-8D3A-A755F21E3894 Q28087788-C568E696-BE32-4675-A0DC-B0C1BEFC120C Q30365242-65948B5C-689A-4506-9FD9-9432CB5E89A7 Q30397854-EEF4E498-0831-41A1-ADAB-68D77797A0DC Q33629810-6267C9D1-C783-4A9D-8C07-9BEF7033FF6D Q33743284-F8B4380E-C43E-4310-A196-EDA2E98F1F8A Q33783760-01940A98-BB9C-41CE-9F66-0CD6AC54A52E Q33838209-0A635EF6-6E77-4BE9-9344-2EF275AB2D86 Q33890178-515197BE-712D-4160-B592-415062397ABB Q33890852-134A004C-BC9A-45C2-BEAA-D2F7E0788F3A Q33962567-C3CCBB24-FBCE-4F33-8A5C-A67DEE1DE753 Q34092070-3176D3B0-C3EE-49D9-BAB4-1AB5D73FC3E1 Q34368537-C5663C8A-A277-4F37-BB39-CA96DD5D101D Q34386867-C6EEC360-429D-42EA-801D-98B53E604DFB Q34753755-F3B45F21-2BD8-4177-AA04-3C6751DB049C Q35344118-844EBEC4-8D11-4A83-A9D0-478BB6F8BB9D Q35492192-B521B34F-3BBA-4C37-A859-B02EC20FE790 Q35766346-7BD1C6D2-407A-405B-9DFE-4FA4D4AF6B02 Q35768368-F8826129-ADA9-4E08-94D0-046D8CBE0716 Q35936707-2DD2593C-D36C-463C-B21C-867D9A994CFB Q35937943-C6F81E2B-19FC-4109-99E7-46FFC1A52EA4 Q36158846-F79E74F3-5A79-4378-A6F9-0F485CAA0D1D Q36366132-011B6FC3-9891-4719-9AA3-4E924B607EE8 Q37418094-BADC05DA-E750-47A5-97A7-EB8AA353979A Q37629298-C1857C27-A16D-469C-BEF7-1C5558F95918 Q38130337-FA7A5C54-FB72-4E94-95F2-D2F16BFF4FBC Q38137141-EC6FABD5-53BA-4985-8E81-CD77C76EB7D1 Q38154255-E58D80CF-EA4D-464D-9AEC-4C5156E47D98 Q38194114-D00DD1EB-AA00-4590-A60B-90560DA274E3 Q38209841-9DF5C101-A00B-4A5C-A28C-BB044ECE601C Q38303157-B57FFB56-B326-4D84-BF2D-CAB48B91438D Q38371305-994D0DD6-4880-4622-B5EA-43D65FF395AA Q38432438-DCECDFA8-310E-4FF6-861A-0FB5A3A3E8EF

P2860

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q27012625

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Combination bronchodilator the ...... obstructive pulmonary disease

@ast

Combination bronchodilator the ...... obstructive pulmonary disease

@en

Combination bronchodilator the ...... obstructive pulmonary disease

@nl

type

label

Combination bronchodilator the ...... obstructive pulmonary disease

@ast

Combination bronchodilator the ...... obstructive pulmonary disease

@en

Combination bronchodilator the ...... obstructive pulmonary disease

@nl

prefLabel

Combination bronchodilator the ...... obstructive pulmonary disease

@ast

Combination bronchodilator the ...... obstructive pulmonary disease

@en

Combination bronchodilator the ...... obstructive pulmonary disease

@nl

P1433

Q27012625-54A433E8-8728-4390-BD99-AB3C40C9FEDB

P1476

Q27012625-BBE2B1B3-EA2F-449A-A1F2-846509806C91

P2093

Q27012625-022287AF-0475-490E-8782-78E55CA44CE9

Q27012625-2A643B2D-EEC9-4208-8A18-B43CA21BDB1A

P275

Q27012625-7CA37486-E632-4214-8C73-B0F028521FC2

P2860

Q27012625-00C55191-7500-4394-8D47-AAD0174AF9E8

Q27012625-04A81A68-D9B2-4791-B394-72E1FC0571C7

Q27012625-05073370-9788-4B30-85AF-8666C662D76E

Q27012625-0B6B36B7-6A42-429A-AFDE-863564364318

Q27012625-128F3097-18B1-4B3C-9BAD-B51B60AB72BB

Q27012625-13043D09-3EBE-46D1-AC93-0E686E25D576

Q27012625-1317F074-09DE-4280-9DAF-11C61BFD95DD

Q27012625-1BE3E8ED-79B2-419F-9314-8199CB89A8AD

Q27012625-1D9F7D79-2FEC-43CD-8194-425BEAE5E467

Q27012625-23C6F02C-3834-43B0-A220-E2C03EF6388A

P2888

Q27012625-1D195500-BF9B-4417-AD49-F88994115DF7

P304

Q27012625-997D4568-138E-4E67-9942-C6AD16D7BE4C

P31

Q27012625-458D15F4-FAE2-4904-9CC4-961EF1760D91

Q27012625-FB319115-E957-463A-B231-6EFAE484F723

P3181

Q27012625-D3578256-9A9C-494F-BF1E-3F9E25C07FC1

P356

Q27012625-BC453B77-B34A-404B-A748-C9CE239B46E6

P407

Q27012625-71822BEF-4B43-4E1D-9F77-6C12617A361F

P478

Q27012625-6CD96C1A-2F65-4C5D-BBB6-DAE31E9B29B2

P577

Q27012625-909D0F9B-89D1-4AF7-99F4-8351E083EBFA

P5875

Q27012625-9B205A51-5AF6-420D-8FA8-5043C0C111B1

P6179

Q27012625-224DB4BF-4781-4F9A-853D-FCA7E06D751F

P698

Q27012625-3A551798-54E3-4C32-BAD3-036A57EA2B21

P921

Q27012625-1C6B2F44-0504-4CE2-926C-5CBD73A1A928

Q27012625-E8000A1E-A985-437A-B3D0-12504963B72E

P932

Q27012625-379E361E-95AD-4FA4-AEB7-C115BA27867C

P3181

P356

1465-9921-14-49

P1433

Respiratory Research

P1476

Combination bronchodilator the ...... obstructive pulmonary disease

@en

P2093

Donald P Tashkin

http://www.w3.org/2001/XMLSchema#string

Gary T Ferguson

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease

β(2) -adrenoceptor agonists: current and future direction

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.

The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.

Impact of bronchodilator therapy on exercise tolerance in COPD.

Improving adherence with inhaler therapy in COPD.

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

A review of the development of Respimat Soft Mist Inhaler.

P2888

1465-9921-14-49

P304

49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

226423

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1465-9921-14-49

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236652600

http://www.w3.org/2001/XMLSchema#string

P6179

1051849337

http://www.w3.org/2001/XMLSchema#string

P698

23651244

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

mechanism of action

P932

3651866

http://www.w3.org/2001/XMLSchema#string